Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 1,300,000 shares, an increase of 20.4% from the December 31st total of 1,080,000 shares. Based on an average daily trading volume, of 619,100 shares, the days-to-cover ratio is currently 2.1 days.

Insider Buying and Selling

In other news, CEO Daniel R. Passeri bought 30,000 shares of Cue Biopharma stock in a transaction that occurred on Monday, December 16th. The shares were acquired at an average price of $1.03 per share, with a total value of $30,900.00. Following the completion of the purchase, the chief executive officer now directly owns 164,578 shares in the company, valued at $169,515.34. The trade was a 22.29 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 12.26% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cue Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in shares of Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company's stock valued at $385,000 after acquiring an additional 16,371 shares in the last quarter. Sigma Planning Corp grew its position in Cue Biopharma by 11.4% during the 4th quarter. Sigma Planning Corp now owns 447,175 shares of the company's stock valued at $487,000 after purchasing an additional 45,850 shares during the last quarter. Good Life Advisors LLC increased its stake in Cue Biopharma by 23.1% during the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company's stock valued at $303,000 after purchasing an additional 75,000 shares in the last quarter. GSA Capital Partners LLP raised its holdings in Cue Biopharma by 5.1% in the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company's stock worth $221,000 after buying an additional 14,104 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Cue Biopharma during the second quarter valued at approximately $66,000. Hedge funds and other institutional investors own 35.04% of the company's stock.

Cue Biopharma Stock Performance

Shares of Cue Biopharma stock remained flat at $1.41 during midday trading on Wednesday. The company had a trading volume of 205,693 shares, compared to its average volume of 371,569. The company has a market capitalization of $89.32 million, a P/E ratio of -1.57 and a beta of 1.66. The company's 50 day moving average is $1.22 and its 200 day moving average is $1.06. Cue Biopharma has a one year low of $0.45 and a one year high of $2.58. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.22 and a current ratio of 2.22.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.